HAVCR2 and melanoma: Several clinical trials are currently evaluating anti-TIM-3 therapies, like sabatolimab (anti-TIM-3), in combination with spartalizumab (anti-PD-1) in advanced melanoma [35], indicating its potential as a critical target for overcoming resistance mechanisms.